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Abstract. 
Lymphoepithelioma-like carcinoma (LELC) of the lung is a rarely occurring disease, and 
only about 170 cases have been reported in the literature. Histologically, it is indistinguishable 
from non-keratinizing undifferentiated (Type III) nasopharyngeal carcinoma (NPC). Both can-
cers are associated with Epstein-Barr virus (EBV). However, clinicians should look to exclude 
NPC before the diagnosis of primary pulmonary LELC is made. Here, we report a 72-year-old 
man suffering from main pulmonary LELC with multiple small pleural nodules and type III 
NPC. However, unusual initial presentation raised the question whether the patient had meta-
static NPC or double cancer. We reviewed the current evidence regarding the association of 
NPC and another EBV-related malignancy, the treatment of pulmonary LELC, and the epide-
miology of NPC whose initial presentation is symptomatic lung metastasis. 
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病例報告  
肺部類淋巴上皮細胞癌與鼻咽癌—轉移性腫瘤，抑或雙原發性腫瘤 
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中文摘要 
  肺原發類淋巴上皮細胞癌(Lymphoepithelioma-like carcinoma)為少見之癌症；到目前為
止，文獻報告僅約 170 例。在組織病理學上，類淋巴上皮細胞癌與典型之第三型鼻咽癌
無法區分。而這二種腫瘤都與艾伯斯坦-巴爾病毒(EBV)有關。一般而言，要診斷肺原發
類淋巴上皮細胞癌需排除鼻咽癌轉移的可能性。我們在此提出一個案例報告，這是一個
72 歲男性病患，同時發現有肺部類淋巴上皮細胞癌及鼻咽癌；但病人臨床表現與典型之
鼻咽癌不同，因此產生診斷上的疑慮－是鼻咽癌併肺轉移，抑或是鼻咽癌及肺原發類淋
巴上皮細胞癌同時發生？我們將回顧以有症狀之肺轉移為表現之鼻咽癌的流行病學，目
前文獻有關鼻咽癌與第二個原發 EBV 相關惡性腫瘤相關性的資料，及肺原發類淋巴上皮
細胞癌目前的治療建議。 
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INTRODUCTION 
A lymphoepithelioma-like carcinoma (LELC), 
characterized by a carcinoma with stromal heavy 
lymphocyte infiltration, is one of the histological pat-
terns observed in patients with Epstein-Barr virus 
(EBV)-associated carcinoma [1]. LELC has been re-
ported in breast [2], skin [3], ureter [4], urinary blad-
der [5], pharynx, and foregut derivatives including the 
oral cavity, salivary glands, thymus, lungs, and stom-
ach [6]. Nonkeratinizing undifferentiated (Type III) 
nasopharyngeal carcinoma (NPC) belong to this his-
topathologic type. Lymphoepithelioma-like carcinoma 
of the lung was first reported in 1987 [7]. A large ma-
jority of pulmonary LELC cases are found in Oriental 
populations, with nearly two-thirds reported in Taiwan, 
Southern China, and Hong Kong [8]. In the literature, 
most authors have suggested that NPC be ruled out 
before a diagnosis of primary LELC is made. 
Herein we report a 72-year-old man who had main 
pulmonary LELC with multiple small lung nodules 
and type III NPC. We will review the epidemiology of 
NPC whose initial presentation is symptomatic lung 
metastasis, current evidence of the association be-
tween NPC and another EBV-related malignancy, and 
the treatment of pulmonary LELC. Additionally, the 
differential diagnosis between NPC with lung metas-
tases and double cancer will also be discussed. 
 
CASE REPORT 
The patient’s medical history noted an aggravating 
intermittent productive cough since 2008, when he 
was 72 years old. In May, 2009, chest film and chest 
computed tomography (CT) disclosed a 42 mm mass 
at the patient’s left lower lung and pleural nodules  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The chest film showed a mass at the left 
lower lung field (A, black arrows) and the 
chest CT disclosed a 42 mm mass at the 
left lower lung (B, white wide arrow) and 
pleural nodules (B, white arrow) 
 
 
(Figure 1). He underwent a CT-guided biopsy of the 
lung, which revealed chronic inflammation; further-
more, a positron emission tomography (PET) scan 
found hypermetabolic lesions at the nasopharynx, left  
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Figure 2. The PET revealed hypermetabolic lesions at the nasopharynx (A), left neck (B), left lung, pleura, chest 
wall, mediastinal and right hilar regions (not shown) 
 
 
neck, left lung, pleura, chest wall, mediastinal and 
right hilar regions (Figure 2). The results of a bron-
choscopic biopsy indicated chronic inflammation. 
Subsequently, a video-assisted thoracic surgery (VATS) 
biopsy of the left pleura showed lymphoepithelio-
ma-like carcinoma, cytokeratin (+), and EBER (+) 
(Figures 3A,3B). A nasopharyngeal biopsy also showed 
non-keratinizing carcinoma (Figures 3C,3C). 
Since July, 2009, the patient had received pallia-
tive chemotherapy. His left pleural effusion decreased 
after two courses of carboplatin plus 5-fluorouracil. 
Subsequently, he used oral uracil and Tegafur irregu-
larly for nine months, but noticed that his ear stuffi-
ness, productive cough and left chest wall pain were 
all worsening. The patient’s neck magnetic resonance 
imaging (MRI) and chest CT in March, 2010 reported 
progression of his disease. From May to September 
2010, three courses of carboplatin plus 5-fluorouracil 
were administered to the patient. His symptoms im-
proved and the disease seemed have stabilized, ac-
cording to results of a CT scan. Thereafter, the patient 
was prescribed oral cyclophosphamide at a dosage of 
50 mg per day. However, his chest pain soon returned, 
and in November 2010 the patient resumed treatment 
with carboplatin plus 5-fluorouracil. Between No-
vember 2010 and June, 2012, he underwent 17 cours-
es of treatment in this 18-month period. The left chest 
wall and its protruding painful lesion improved after 
each of treatment, but returned after only three to four 
weeks. CT scans also showed disease progression, but 
the patient was reluctant to shift to cisplatin-based 
treatment. 
He had sudden-onset bilateral lower leg weakness 
in July, 2012. An MRI of the spine showed invasion to 
T7-11 with epidural extension. Palliative radiotherapy 
to T2-T12, 30Gy in 10 fractions, was administered. 
Subsequently, the patient had five treatment sessions 
of cisplatin plus 5-FU from July to October; however, 
his paraparesis had not improved at the end of these 
treatments, and the painful mass on his chest wall was 
also enlarged. Radiotherapy applied to the left chest 
wall mass transiently improved pain control. Paclitaxel 
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Figure 3. H&E stain (A, 400X magnification) and EBER ISH (B, 200X magnification) of pleural biopsy, and 
H&E stain (C, 400X magnification) and EBER ISH (D, 200X magnification) of nasopharynx biopsy 
 
 
and cisplatin was given in December 2012. The pa-
tient felt better but hesitated to continue the course of 
treatment. Thereafter, a new palpable left axilla mass 
was noted and left hip pain also developed.  
He turned to hospice care in January, 2013 and 
was admitted in February, 2013 after visited the 
emergency department with symptoms of fever and 
chill. Upon admission, the patient presented as clearly 
conscious, cachexia-like in appearance with a blood 
pressure of 130/78 mmHg. Treatment with cefemeta-
zole was continued for urinary tract infection and the 
patient’s fever subsided. However, a urine culture 
yielded Enterococcus faecalis and Escherichia coli. 
Although the patient’s blood culture contained no 
pathogen, his blood pressure dropped gradually and 
thereafter he passed away.  
 
DISCUSSION 
Nasopharyngeal carcinoma has a tendency for 
early metastatic spread [9,10]. Apparently, 75% to 
90% of NPC patients have lymph node metastases at 
the time of diagnosis. However, distant metastasis at 
diagnosis is relatively rare. According to data gener-
ated from observation of the Taiwanese population, 
6.8~15.5% of patients with NPC have clinical evi-
dence of distant metastases when initially evaluated 
[10,11]. The most common sites of initial metastases 
were bone (82%), followed by liver (35%) and lung 
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(14%) [11]. The patients with NPC usually present 
with local symptoms including neck masses, blood 
tinged sputum/rhinorrhea, nasal symptoms (nasal ob-
struction or increased nasal discharge), aural symp-
toms (tinnitus, stuffiness, and hearing loss), headache, 
and cranial nerve dysfunction [10]. This would sug-
gest that the distal metastatic lesions at diagnosis 
rarely led to symptoms. However, these asymptomatic 
lesions are often detected at the staging workup phase.  
In this patient, he initially presented with pulmonary 
symptoms. Moreover, the usual pattern of pulmonary 
metastases of NPC is the presence of multiple lung 
nodules. Our patient had a 44 mm main mass in the 
left lower lung and pleural nodules. These features are 
unusual for NPC and raised the question whether he 
had a metastatic NPC or double cancer. Furthermore, 
because his NPC was staged as T3N1, with a relative-
ly small tumor and a solitary neck lymph node metas-
tasis, the risk of distant metastasis is low.  
Lymphoepithelioma-like carcinoma (LELC) of the 
lung was first reported in 1987 [7]. There were ap-
proximately 170 cases of LELC reported in the litera-
ture through 2012 [12]. Histologically, it is indistin-
guishable from non-keratinizing undifferentiated 
(Type III) nasopharyngeal carcinoma. In fact, an etio-
logical association with EBV has been suggested.  
The demonstration of abundant EBV-encoded small 
nuclear RNA (EBER) by in situ hybridization (ISH) in 
the majority of tumor cells has become the standard 
test to show the tumor-specific association of EBV. In 
LELC of the lung patients with available EBER re-
sults, 86% (123/143) cases have positive EBER [8]. 
The predominant clinical presentations were cough 
(47%) and incidental finding in asymptomatic subjects 
(22%). Other symptoms on presentation included 
chest pain (13%), dyspnea (5%), weight loss (5%), 
night sweat (3%), joint pain (3%) and fever (2%). 
NPC and LELC of the lung are both associated with 
EBV. Therefore, it would appear reasonable that two 
EBV-related malignancies synchronously could mani-
fest in one patient. However, according to two cancer 
registry studies from Taiwan [13] and Singapore [14], 
elevated standardized incidence ratios (SIRs) were 
observed in second primary cancers of the oral/  
pharyngeal area, salivary gland, sarcoma, skin cancers, 
and leukemia/lymphoma [13]. However, there was no 
evidence of association with other Epstein-Barr vi-
rus-related cancers [14,15].   
To differentiate one primary tumor with distant 
metastases or two primary tumors, molecular study 
may provide additional important evidence. Sequenc-
ing the BZLF1 [16,17], EBER or EBNA1 [18] genes of 
EBV of the nasopharyngeal tumor and pulmonary tu-
mor could identify the EBV strains in the malignant 
tissues. If the strains of two tissues are not identical, a 
diagnosis of two primary cancers is more plausible.  
However, it remains unclear how EBV is involved in 
oncogenesis. One strain of EBV in two primary can-
cers is also possible. Although only 17.1% of NPC 
tumors were positive for mutations in common onco-
genes [19], comparing the oncogene mutational pro-
file (e.g. PIK3CA, NRAS, KIT, PDGFRA, ABL, HRAS, 
EGFR, and BRAF) of the two tissues may provide 
additional clues for a more precise diagnosis. Howev-
er, at this time, such molecular examinations are only 
utilized in a study setting, with no commercial kits yet 
available. Therefore, it is not practicable in a clinical 
setting. 
The primary treatment for early stage of lung 
LELC is surgical resection. For advanced or metastat-
ic stages of lung LELC, there is no standard treatment 
consensus due to its rarity. In a clinical series, chemo-
therapy with cisplatin and 5-fluorouracil in seven pa-
tients with advanced disease achieved a 71.4% partial 
response rate [20]. In another series, the response rates 
to chemotherapy with 5-fluorouracil/leucovorin/cis-
platin were 60% partial response [21]. The median 
survival time was 23.4 ± 4.7 months, apparently long-
er than those patients with advanced non-LELC non- 
small cell lung cancer who received platinum-based 
doublet chemotherapy. The study of a case series in 
Taiwan also recommended platinum-based doublet 
252 M. K. Chuang et al./JCRP 2(2015) 248-254
chemotherapy as the first-line treatment [12]. Radio-
therapy also should be considered, and 5000 to 7000 
cGy is frequently applied. The median overall survival 
for patients with stage III and with stage IV disease is 
3.4 years [12].   
In the presented patient, our assessment of NPC, 
T3N1M1, at stage IVC was the more commonly ac-
cepted diagnosis, but we could not rule out the possi-
bility of synchronous second primary cancers (NPC, 
T3N1M0, stage III, and primary pulmonary LELC, 
T2aN0M1a, stage IV). The primary treatment for both 
diagnoses was similar: systemic chemotherapy. If a 
patient were younger and had good performance status, 
more aggressive local and systemic treatments might 
be considered.   
In summary, we presented a patient with NPC and 
pulmonary LELC. Arising from his unusual symptoms 
and overall medical evaluation, synchronous double 
cancer should also be considered. By current WHO 
diagnostic criteria of LELC, any sites of LELC will be 
classified as metastasis of NPC if the nasopharynx 
was positive for LELC. However, this may occasion-
ally be misleading, causing clinicians to overlook the 
possibility of multiple EBV-related carcinogenesis in 
the same patient.  
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